BR9713465A - Inibidores metalotprotease de amina cìclica sibstituìda - Google Patents

Inibidores metalotprotease de amina cìclica sibstituìda

Info

Publication number
BR9713465A
BR9713465A BR9713465-1A BR9713465A BR9713465A BR 9713465 A BR9713465 A BR 9713465A BR 9713465 A BR9713465 A BR 9713465A BR 9713465 A BR9713465 A BR 9713465A
Authority
BR
Brazil
Prior art keywords
inhibitors
metallotprotease
cytically
substituted amine
compounds
Prior art date
Application number
BR9713465-1A
Other languages
English (en)
Inventor
Michael George Nartchus
Biswanath De
Stanislaw Pikul
Neil Gregory Almstead
Roger Gunnard Bookland
Yetunde Olabisi Taiwo
Menyan Cheng
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9713465A publication Critical patent/BR9713465A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Confectionery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES METALOPROTEASE DE AMINA CìCLICA SUBSTITUìDA"<D>. A invenção proporciona compostos que são úteis como inibidores de mateloproteases, e que são eficazes no tratamento de condições caracterizadas por excesso de atividade destas enzimas. Em particular, a presente invenção refere-se a um composto tendo uma estrutura de acordo com a Fórmula (I). Também estão descritos compostos, composições farmacêuticas e processos de tratamento de doenças caracterizadas por atividade metaloprotease, utilizando estes compostos ou as composições farmacêuticas contendo as mesmas.
BR9713465-1A 1996-08-28 1997-08-22 Inibidores metalotprotease de amina cìclica sibstituìda BR9713465A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2484296P 1996-08-28 1996-08-28
PCT/US1997/014555 WO1998008815A1 (en) 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BR9713465A true BR9713465A (pt) 2000-03-28

Family

ID=21822685

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713465-1A BR9713465A (pt) 1996-08-28 1997-08-22 Inibidores metalotprotease de amina cìclica sibstituìda

Country Status (29)

Country Link
US (6) US6417219B1 (pt)
EP (1) EP0927161B1 (pt)
JP (2) JP3541043B2 (pt)
KR (1) KR100323272B1 (pt)
CN (1) CN1232451A (pt)
AT (1) ATE226193T1 (pt)
AU (1) AU741893B2 (pt)
BR (1) BR9713465A (pt)
CA (1) CA2263928A1 (pt)
CO (1) CO4900036A1 (pt)
CZ (1) CZ63199A3 (pt)
DE (1) DE69716449T2 (pt)
DK (1) DK0927161T3 (pt)
ES (1) ES2201318T3 (pt)
HU (1) HUP0000478A3 (pt)
ID (1) ID18143A (pt)
IL (1) IL128666A (pt)
MY (1) MY116959A (pt)
NO (1) NO315371B1 (pt)
NZ (1) NZ334256A (pt)
PE (1) PE109098A1 (pt)
PL (1) PL331802A1 (pt)
PT (1) PT927161E (pt)
RU (1) RU2221782C2 (pt)
SK (1) SK25099A3 (pt)
TR (1) TR199900431T2 (pt)
TW (1) TWI232218B (pt)
WO (1) WO1998008815A1 (pt)
ZA (1) ZA977698B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
CZ63199A3 (cs) * 1996-08-28 1999-08-11 The Procter & Gamble Company Sloučeniny typu substituovaných cyklických aminů jako inhibitory metaloproteáz, způsob jejich přípravy a použití jako léčiv
US6872742B2 (en) * 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
EP1053226A1 (en) 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
CN1301265A (zh) 1998-05-14 2001-06-27 杜邦药品公司 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1117372A2 (en) * 1998-09-30 2001-07-25 The Procter & Gamble Company Method of treating hair loss using sulfonamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1165530A2 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
CN1349498A (zh) 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂
WO2000058304A1 (en) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2001010837A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent sulfonamides
WO2001010838A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent compounds
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
KR100372757B1 (ko) * 2000-04-07 2003-02-17 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
CN1536989A (zh) 2000-06-30 2004-10-13 促进全身健康
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
BR0112580A (pt) 2000-07-19 2003-06-17 Hoffmann La Roche Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
BR0112655A (pt) 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirrolidino como inibidores de metaloproteases
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
WO2003037852A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
DE60231425D1 (de) 2001-11-13 2009-04-16 Shiseido Co Ltd Azabicycloverbindung, matrixmetallproteaseinhibitor und zubereitung für haut
US20030158186A1 (en) * 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
JP2007521274A (ja) * 2003-06-20 2007-08-02 アルコン，インコーポレイテッド 複数成分の組み合わせを用いる加齢性黄斑変性の処置
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
EP2336107B1 (en) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Proton pump inhibitors
JP2008530197A (ja) * 2005-02-18 2008-08-07 イノディア インク． ４−ヒドロキシイソロイシンの類似体及びその使用
EP2327692B9 (en) 2005-08-30 2014-06-04 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
DK1966130T3 (da) 2005-12-23 2014-02-10 Zealand Pharma As Modificerede lysin-mimetiske forbindelser
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
PE20110300A1 (es) 2008-08-27 2011-06-16 Takeda Pharmaceutical Compuestos de pirrol como inhibidores de la bomba de protones
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
EP2763972A1 (en) * 2011-10-04 2014-08-13 Institut National de la Santé et de la Recherche Médicale (INSERM) New apoptosis inducing compounds
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
KR20190049865A (ko) 2016-09-20 2019-05-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Trpv4 길항제
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954158A (en) * 1983-08-16 1990-09-04 University Of Georgia Research Foundation, Inc. 2,3-methanoproline
ZA877471B (en) * 1986-10-08 1988-04-05 Bristol-Myers Company 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5795890A (en) * 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
CZ63199A3 (cs) * 1996-08-28 1999-08-11 The Procter & Gamble Company Sloučeniny typu substituovaných cyklických aminů jako inhibitory metaloproteáz, způsob jejich přípravy a použití jako léčiv
US6376506B1 (en) * 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6261775B1 (en) * 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Also Published As

Publication number Publication date
PT927161E (pt) 2003-12-31
TR199900431T2 (xx) 1999-04-21
US6858628B2 (en) 2005-02-22
DE69716449T2 (de) 2003-08-07
PL331802A1 (en) 1999-08-02
ES2201318T3 (es) 2004-03-16
PE109098A1 (es) 1999-02-19
MY116959A (en) 2004-04-30
EP0927161A1 (en) 1999-07-07
US20020061877A1 (en) 2002-05-23
US6417219B1 (en) 2002-07-09
CA2263928A1 (en) 1998-03-05
CZ63199A3 (cs) 1999-08-11
TWI232218B (en) 2005-05-11
ID18143A (id) 1998-03-05
JP3541043B2 (ja) 2004-07-07
EP0927161B1 (en) 2002-10-16
DK0927161T3 (da) 2003-02-17
JP2004115531A (ja) 2004-04-15
ATE226193T1 (de) 2002-11-15
AU4074197A (en) 1998-03-19
US20050101567A1 (en) 2005-05-12
AU741893B2 (en) 2001-12-13
KR100323272B1 (ko) 2002-02-06
WO1998008815A1 (en) 1998-03-05
JP2000516955A (ja) 2000-12-19
IL128666A0 (en) 2000-01-31
HUP0000478A3 (en) 2000-10-30
HUP0000478A2 (hu) 2000-09-28
RU2221782C2 (ru) 2004-01-20
US20030191163A1 (en) 2003-10-09
DE69716449D1 (de) 2002-11-21
US20050154019A1 (en) 2005-07-14
US20020072517A1 (en) 2002-06-13
NO315371B1 (no) 2003-08-25
NZ334256A (en) 2000-11-24
NO990855L (no) 1999-04-23
NO990855D0 (no) 1999-02-23
KR20000035922A (ko) 2000-06-26
CN1232451A (zh) 1999-10-20
US6569855B2 (en) 2003-05-27
SK25099A3 (en) 2000-02-14
HK1020962A1 (en) 2000-05-26
CO4900036A1 (es) 2000-03-27
IL128666A (en) 2005-09-25
ZA977698B (en) 1998-02-23

Similar Documents

Publication Publication Date Title
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
BR9713182A (pt) Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
BR0010555A (pt) Inibidores de neuraminidases
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
YU56995A (sh) Soli derivata indola
ATE284690T1 (de) Antithrombotische diamine
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR9909620A (pt) Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo
EA199900632A1 (ru) 2-амино-6-(2-замещенные-4-фенокси)-замещенные-пиридины
BR9712792A (pt) Inibidores de metaloprotease bidentada.
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0212535A (pt) Compostos e composições como inibidores de catepsina
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
ATE253359T1 (de) Antithrombotische mittel
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
DK0998471T3 (da) Heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
ATE286395T1 (de) Antithrombotische mittel
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/40, A61K 31/4025, A61K 41/78, A61K 31/428, A61K 31/4439, A61K 31/445, A61P 1/04, A61P 9/00, A61P 17/00, A61P 19/00, A61P 27/02, A61P 29/00, A61P 35/00, A61P 43/00, C07D 207/16, C07D 207/48, C07D 401/04, C07D 401/06, C07D 401/12, C07D 403/04, C07D 403/12, C07D 413/04, C07D 417/04

Ipc: A61K 31/40 (2007.01), A61K 31/4025 (2007.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]